Patents Assigned to Immune Disease Institute, Inc.
-
Publication number: 20140127214Abstract: The invention provides natural IgM antibody inhibitors that may be used to treat various inflammatory diseases or disorders.Type: ApplicationFiled: April 9, 2013Publication date: May 8, 2014Applicants: Immune Disease Institute, Inc., The Brigham and Women's Hospital, Inc., President and Fellows of Harvard CollegeInventors: Immune Disease Institute, Inc., President and Fellows of Harvard College, The Brigham and Women's Hospital, Inc.
-
Publication number: 20140093542Abstract: Embodiments of the inventions relate to modulating NFAT activity, modulating store-operated Ca2+ entry into a cell and treating and/or preventing hyperactivity or inappropriate immune response by inhibiting the expression or activities of septin 4 (SEPT 4) and septin 5 (SEPT 5) proteins involved in the calcineurin/NFAT axis and T-cell activation.Type: ApplicationFiled: October 10, 2011Publication date: April 3, 2014Applicant: IMMUNE DISEASE INSTITUTE, INC.Inventors: Anjana Rao, Patrick Hogan, Sonia Sharma
-
Publication number: 20140073687Abstract: Aspects of the invention described herein relate to synthetic, modified RNAs and their use in vivo to modulate gene expression. Aspects of the invention further relate to the use of these synthetic, modified RNAs in myocytes, cardiomyoctes, and tumors.Type: ApplicationFiled: March 12, 2012Publication date: March 13, 2014Applicants: IMMUNE DISEASE INSTITUTE, INC., THE GENERAL HOSPITAL CORPORATIONInventors: Kenneth R. Chien, Leon M. Ptaszek, Kathy Oi-Lan Lui, Lior Zangi, Wataru Ebina, Derrick J. Rossi
-
Publication number: 20130158101Abstract: Embodiments of the inventions relate to modulating NFAT activity, modulating store-operated Ca2+ entry into a cell and treating and/or preventing hyperactivity or inappropriate immune response by inhibiting the expression or activities of proteins involved in the calcineurin/NFAT axis.Type: ApplicationFiled: February 7, 2013Publication date: June 20, 2013Applicant: IMMUNE DISEASE INSTITUTE, INC.Inventor: IMMUNE DISEASE INSTITUTE, INC.
-
Publication number: 20130136732Abstract: This invention relates to a pharmaceutical composition having thrombolytic activity comprising ADAMTS13, and to methods for treating or preventing a disorder associated with the formation and/or the presence of one or more thrombus and to methods of disintegrating one or more thrombus in a patient in need thereof. Furthermore, the invention relates to the use of a pharmaceutically effective amount of ADAMTS13 for the preparation of a pharmaceutical composition for treating or preventing a disorder associated with the formation or the presence of one or more thrombus and for disintegrating one or more thrombus in a patient in need thereof.Type: ApplicationFiled: January 22, 2013Publication date: May 30, 2013Applicants: Baxter Healthcare S.A., Immune Disease Institute, Inc., Baxter International Inc.Inventors: Baxter Healthcare S.A., Baxter International Inc., Immune Disease Institute, Inc.
-
Publication number: 20130129752Abstract: Disclosed herein are is a leukocyte-selective delivery agent comprising, a targeting moiety that selectively binds LFA-I, a protein carrier moiety covalently linked to the targeting moiety, and a therapeutic agent associated with the carrier moiety. The delivery agent may be further selective for activated leukocytes, wherein the targeting moiety selectively binds LFA-I in its activated conformation. The targeting moiety comprises an antibody or functional fragment thereof, such as an scFV. Examples of antibodies or fragments thereof which selectively bind LFA-I activated conformation bind to the locked open I domain of LFA-I, or binds to the leg domain of the ?2 subunit of LFA-I ((ILP2)—The antibody or functional fragment thereof may alternatively bind non-selectively to both low affinity and high affinity LFA-I. Examples of a non-protein carrier are a basic polypeptide such as protamine or a functional fragment thereof. One such fragment is RSQSRSRYYRQRQRSRRRRRRS.Type: ApplicationFiled: April 25, 2007Publication date: May 23, 2013Applicant: IMMUNE DISEASE INSTITUTE, INC.Inventors: Dan Peer, Motomu Shimaoka, Judy Lieberman
-
Patent number: 8399185Abstract: Disclosed are methods of identifying an agent that modulates an NFAT regulator protein. One such method comprises contacting at least one test agent with a recombinant cell comprising at least one NFAT regulator protein or fragment or derivative thereof, assessing the effect of the test agent on an activity, interaction, expression, or binding to the NFAT regulator protein or fragment or derivative thereof, and identifying the test agent that has an effect on an activity, interaction, expression, or binding to the NFAT regulator protein or fragment or derivative thereof, whereby the identified test agent is characterized as an agent that modulates an NFAT regulator protein.Type: GrantFiled: January 5, 2007Date of Patent: March 19, 2013Assignee: Immune Disease Institute, Inc.Inventors: Anjana Rao, Stefan Feske, Patrick Hogan, Yousang Gwack
-
Patent number: 8394778Abstract: Embodiments of the inventions relate to modulating NFAT activity, modulating store-operated Ca2+ entry into a cell and treating and/or preventing hyperactivity or inappropriate immune response by inhibiting the expression or activities of proteins involved in the calcineurin/NFAT axis.Type: GrantFiled: October 8, 2010Date of Patent: March 12, 2013Assignee: Immune Disease Institute, Inc.Inventors: Anjana Rao, Patrick Hogan, Sonia Sharma
-
Publication number: 20130040845Abstract: Embodiments of the invention herein relate to methods of studying binding interactions between two entities and methods for screening of modulators of such binding interactions, in particular, the protein-protein interaction observed in receptor-ligand interactions.Type: ApplicationFiled: February 14, 2011Publication date: February 14, 2013Applicant: IMMUNE DISEASE INSTITUTE, INC.Inventors: Timothy A. Springer, Jongseong Kim
-
Publication number: 20120322865Abstract: Described herein are synthetic, modified RNAs for changing the phenotype of a cell, such as expressing a polypeptide or altering the developmental potential. Accordingly, provided herein are compositions, methods, and kits comprising synthetic, modified RNAs for changing the phenotype of a cell or cells. These methods, compositions, and kits comprising synthetic, modified RNAs can be used either to express a desired protein in a cell or tissue, or to change the differentiated phenotype of a cell to that of another, desired cell type.Type: ApplicationFiled: August 21, 2012Publication date: December 20, 2012Applicant: IMMUNE DISEASE INSTITUTE, INC.Inventors: Derrick Rossi, Luigi Warren
-
Publication number: 20120322864Abstract: Described herein are synthetic, modified RNAs for changing the phenotype of a cell, such as expressing a polypeptide or altering the developmental potential. Accordingly, provided herein are compositions, methods, and kits comprising synthetic, modified RNAs for changing the phenotype of a cell or cells. These methods, compositions, and kits comprising synthetic, modified RNAs can be used either to express a desired protein in a cell or tissue, or to change the differentiated phenotype of a cell to that of another, desired cell type.Type: ApplicationFiled: August 21, 2012Publication date: December 20, 2012Applicant: IMMUNE DISEASE INSTITUTE, INC.Inventors: Derrick Rossi, Luigi Warren
-
Publication number: 20120272343Abstract: This invention relates to knockout mice for the Ca2+ sensor membrane protein STIM-1, STIM-2, or both, as well as cell lines from these knockout mice. Provided herein are various methods of use of isolated with knockout STIM-1 and/or STIM-2.Type: ApplicationFiled: June 29, 2012Publication date: October 25, 2012Applicant: IMMUNE DISEASE INSTITUTE, INC.Inventors: Masatsugu Oh-Hora, Patrick Hogan, Stefan Feske, Anjana Rao
-
Publication number: 20120264231Abstract: The methods and systems described herein are based, in part, on the discovery that STIM modulates calcium release from store-operated channels through a direct interaction with the ORAI channel. Based on this discovery, methods and systems are described herein for identifying an agent that modulates calcium flux through the ORAI channel and/or regulates intracellular calcium via the ORAI channel. The methods and systems can also be used to detect an interaction between STIM and a functional ORAI channel.Type: ApplicationFiled: June 21, 2010Publication date: October 18, 2012Applicant: IMMUNE DISEASE INSTITUTE, INC.Inventors: Patrick Hogan, Yubin Zhou, Anjana Rao, Paul Meraner, Danya Bess Machnes
-
Publication number: 20120258534Abstract: The invention provides a method of RNA interference, which comprises contacting the cell with a fusion protein-double stranded RNA complex, the complex comprising the double stranded RNA segment containing a double stranded RNA of interest and a fusion protein, the fusion protein comprising (1) a targeting moiety, which will specifically binds to a site on a target cell, and (2) a binding moiety, which will bind to the double stranded RNA, wherein the double stranded RNA segment initiates RNA interference in the cell.Type: ApplicationFiled: March 29, 2012Publication date: October 11, 2012Applicant: IMMUNE DISEASE INSTITUTE, INC.Inventors: Judy Lieberman, Erwei Song
-
Patent number: 8168601Abstract: The invention provides a method of RNA interference, which comprises contacting the cell with a fusion protein-double stranded RNA complex, the complex comprising the double stranded RNA segment containing a double stranded RNA of interest and a fusion protein, the fusion protein comprising (1) a targeting moiety, which will specifically binds to a site on a target cell, and (2) a binding moiety, which will bind to the double stranded RNA, wherein the double stranded RNA segment initiates RNA interference in the cell.Type: GrantFiled: August 15, 2005Date of Patent: May 1, 2012Assignee: Immune Disease Institute, Inc.Inventors: Judy Lieberman, Erwei Song
-
Publication number: 20120087973Abstract: The invention provides a microbicidal composition comprising at least one siRNA. The siRNA is an RNA duplex made of one or two molecules. A portion of the siRNA is identical to a target sequence in an essential gene of a virus. The virus may be a herpesvirus, for example, HSV-1 or HSV-2. Preferably, the herpesvirus is HSV-2. The microbicidal composition further comprises a pharmaceutically acceptable carrier. Also included in the invention are methods to prevent and treat viral infections by administration of the microbicidal composition. Preferably, the microbicidal composition is administered transmucosally.Type: ApplicationFiled: March 23, 2011Publication date: April 12, 2012Applicants: President and Fellows of Harvard College, Immune Disease Institute, Inc.Inventors: Judy Lieberman, Deborah Palliser, David Knipe
-
Publication number: 20120059043Abstract: The present invention encompasses the finding that microRNAs (miRNAs) regulate certain key proteins involved in DNA repair. In some embodiments, a miRNA suppresses levels and/or activity of one or more DNA repair proteins. In some such embodiments, such suppression renders cells hypersensitive to certain DNA damage agents (e.g., ?-irradiation and genotoxic drugs, among others). The present invention provides various reagents and methods associated with these findings including, among other things, strategies for treating cell proliferative disorders, certain diagnostic systems, etc.Type: ApplicationFiled: September 18, 2009Publication date: March 8, 2012Applicant: IMMUNE DISEASE INSTITUTE, INC.Inventors: Judy Lieberman, Ashish Lal, Dipanjan Chowdhury
-
Publication number: 20120046346Abstract: Described herein are synthetic, modified RNAs for changing the phenotype of a cell, such as expressing a polypeptide or altering the developmental potential. Accordingly, provided herein are compositions, methods, and kits comprising synthetic, modified RNAs for changing the phenotype of a cell or cells. These methods, compositions, and kits comprising synthetic, modified RNAs can be used either to express a desired protein in a cell or tissue, or to change the differentiated phenotype of a cell to that of another, desired cell type.Type: ApplicationFiled: April 15, 2011Publication date: February 23, 2012Applicant: IMMUNE DISEASE INSTITUTE, INC.Inventors: Derrick Rossi, Luigi Warren
-
Publication number: 20120040851Abstract: The present invention provides systems for identifying, isolating, and/or characterizing targets of micro RNAs.Type: ApplicationFiled: September 18, 2009Publication date: February 16, 2012Applicant: IMMUNE DISEASE INSTITUTE, INC.Inventors: Judy Lieberman, Ashish Lal
-
Publication number: 20110269174Abstract: Disclosed are methods of identifying an agent that modulates an NFAT regulator protein. One such method comprises contacting at least one test agent with a recombinant cell comprising at least one NFAT regulator protein or fragment or derivative thereof, assessing the effect of the test agent on an activity, interaction, expression, or binding to the NFAT regulator protein or fragment or derivative thereof, and identifying the test agent that has an effect on an activity, interaction, expression, or binding to the NFAT regulator protein or fragment or derivative thereof, whereby the identified test agent is characterized as an agent that modulates an NFAT regulator protein.Type: ApplicationFiled: June 15, 2011Publication date: November 3, 2011Applicant: Immune Disease Institute, Inc.Inventors: Anjana RAO, Stefan Feske, Patrick Hogan, Yousang Gwack